Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
作者信息
Alliot Carol
出版信息
J Clin Oncol. 2005 Jun 20;23(18):4237-8; author reply 4238-9. doi: 10.1200/JCO.2004.01.0207.
PMID:15961776
Abstract
摘要
相似文献
1
Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
J Clin Oncol. 2005 Jun 20;23(18):4237-8; author reply 4238-9. doi: 10.1200/JCO.2004.01.0207.
2
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25.
3
4
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
J Clin Oncol. 2006 Jan 20;24(3):370-8. doi: 10.1200/JCO.2005.03.5196.
5
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9.
6
Systemic (adjuvant) treatment of primary breast cancer.
J Assoc Physicians India. 2001 Apr;49:451-3.
7
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.
8
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3.
9
The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
J Clin Oncol. 2005 Sep 20;23(27):6807-9. doi: 10.1200/JCO.2005.02.3952.
10
Optimal chemotherapy for high-risk early-stage breast cancer.
J Clin Oncol. 2010 Jun 1;28(16):e263; author reply e264. doi: 10.1200/JCO.2010.28.1196. Epub 2010 Apr 20.
Zotero 插件